CL2013003365A1 - Pharmaceutical formulation comprising diacylglycerol and / or tocopherol, phosphatidylcholine, biocompatible organic mono-alcoholic solvent comprising ethanol, polar solvent, and a somatostatin analog as active ingredient; process to prepare it; pharmaceutical kit; use in the treatment of acromegaly and cancers, among others. - Google Patents
Pharmaceutical formulation comprising diacylglycerol and / or tocopherol, phosphatidylcholine, biocompatible organic mono-alcoholic solvent comprising ethanol, polar solvent, and a somatostatin analog as active ingredient; process to prepare it; pharmaceutical kit; use in the treatment of acromegaly and cancers, among others.Info
- Publication number
- CL2013003365A1 CL2013003365A1 CL2013003365A CL2013003365A CL2013003365A1 CL 2013003365 A1 CL2013003365 A1 CL 2013003365A1 CL 2013003365 A CL2013003365 A CL 2013003365A CL 2013003365 A CL2013003365 A CL 2013003365A CL 2013003365 A1 CL2013003365 A1 CL 2013003365A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical formulation
- pharmaceutical
- diacylglycerol
- phosphatidylcholine
- tocopherol
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001982 diacylglycerols Chemical class 0.000 title abstract 2
- 239000002798 polar solvent Substances 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 229960001295 tocopherol Drugs 0.000 title abstract 2
- 229930003799 tocopherol Natural products 0.000 title abstract 2
- 235000010384 tocopherol Nutrition 0.000 title abstract 2
- 239000011732 tocopherol Substances 0.000 title abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title abstract 2
- 206010000599 Acromegaly Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
Abstract
La solicitud 201303365 describe a una formulación farmacéutica que comprende una mezcla de baja viscosidad de: (a) 20-80 % en peso de por lo menos un diacilglicerol y/o un tocoferol; (b) 20-80 % en peso de por lo menos una fosfatidilcolina (PC); (c) 5-20 % en peso de por lo menos un solvente mono-alcohólico orgánico biocompatible que comprende etanol; (d) hasta 20 % en peso de un solvente polar, seleccionado desde agua, propilenglicol o mezclas de los mismos; (e) por lo menos un agente activo peptídico de análogo de somatostatina; donde la formulación farmacéutica tiene una viscosidad de 1-1.000 mPas a 20 °C; donde la relación de componentes a:b está dentro del rango 40:60 a 54:46; donde la formulación forma, o es capaz de formar, por lo menos una estructura de fase cristalina líquida luego del contacto con fluido acuoso en exceso. Además, se describe un proceso de preparación de la formulación; su uso para preparar medicamentos; y un kit farmacéutico que comprende a la formulación farmacéutica.Application 201303365 describes a pharmaceutical formulation comprising a low viscosity mixture of: (a) 20-80% by weight of at least one diacylglycerol and / or a tocopherol; (b) 20-80% by weight of at least one phosphatidylcholine (PC); (c) 5-20% by weight of at least one biocompatible organic mono-alcoholic solvent comprising ethanol; (d) up to 20% by weight of a polar solvent, selected from water, propylene glycol or mixtures thereof; (e) at least one somatostatin analog peptide active agent; where the pharmaceutical formulation has a viscosity of 1-1,000 mPas at 20 ° C; where the ratio of components a: b is within the range 40:60 to 54:46; where the formulation forms, or is capable of forming, at least one liquid crystalline phase structure after contact with excess aqueous fluid. In addition, a formulation preparation process is described; its use to prepare medications; and a pharmaceutical kit comprising the pharmaceutical formulation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489886P | 2011-05-25 | 2011-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003365A1 true CL2013003365A1 (en) | 2014-07-25 |
Family
ID=46456496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003365A CL2013003365A1 (en) | 2011-05-25 | 2013-11-22 | Pharmaceutical formulation comprising diacylglycerol and / or tocopherol, phosphatidylcholine, biocompatible organic mono-alcoholic solvent comprising ethanol, polar solvent, and a somatostatin analog as active ingredient; process to prepare it; pharmaceutical kit; use in the treatment of acromegaly and cancers, among others. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US11433120B2 (en) |
| EP (2) | EP2714004B1 (en) |
| JP (2) | JP6265888B2 (en) |
| KR (1) | KR102066755B1 (en) |
| CN (2) | CN108283619B (en) |
| AR (1) | AR086577A1 (en) |
| AU (2) | AU2012260821B2 (en) |
| BR (1) | BR112013030104A8 (en) |
| CA (1) | CA2836847C (en) |
| CL (1) | CL2013003365A1 (en) |
| CO (1) | CO6900117A2 (en) |
| CR (1) | CR20130653A (en) |
| CU (1) | CU20130158A7 (en) |
| DK (1) | DK2714004T3 (en) |
| DO (1) | DOP2013000275A (en) |
| EA (1) | EA036213B1 (en) |
| EC (1) | ECSP13013107A (en) |
| ES (1) | ES2984717T3 (en) |
| FI (1) | FI2714004T3 (en) |
| GT (1) | GT201300292A (en) |
| HR (1) | HRP20240781T1 (en) |
| HU (1) | HUE067389T2 (en) |
| IL (1) | IL229376B (en) |
| LT (1) | LT2714004T (en) |
| MX (1) | MX361716B (en) |
| MY (1) | MY177820A (en) |
| NI (1) | NI201300127A (en) |
| PE (1) | PE20141484A1 (en) |
| PH (1) | PH12013502550A1 (en) |
| PL (1) | PL2714004T3 (en) |
| PT (1) | PT2714004T (en) |
| RS (1) | RS65702B1 (en) |
| SG (1) | SG194865A1 (en) |
| SI (1) | SI2714004T1 (en) |
| TW (1) | TWI624271B (en) |
| WO (1) | WO2012160213A1 (en) |
| ZA (1) | ZA201309653B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| US9107904B2 (en) | 2012-04-05 | 2015-08-18 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| KR102139080B1 (en) * | 2012-05-25 | 2020-07-29 | 카무러스 에이비 | Somatostatin receptor agonist formulations |
| EP2877155B1 (en) | 2012-07-26 | 2020-10-28 | Camurus AB | Opioid formulations |
| IL296882A (en) | 2012-07-26 | 2022-12-01 | Camurus Ab | Opioid compounds |
| WO2018013924A1 (en) | 2016-07-15 | 2018-01-18 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| JP7527785B2 (en) | 2016-09-15 | 2024-08-05 | カムルス エービー | Prostacyclin analogues |
| AU2017336199B2 (en) | 2016-09-27 | 2020-08-20 | Camurus Ab | Mixtures and formulations comprising an alkyl ammonium EDTA salt |
| AU2017370692A1 (en) | 2016-12-07 | 2019-06-06 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CA3082708A1 (en) * | 2017-11-15 | 2019-05-23 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
| CA3092693A1 (en) | 2018-03-02 | 2019-09-06 | Elicio Therapeutics, Inc. | Cpg amphiphiles and uses thereof |
| CN109091451B (en) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | Oil phase liquid crystal gel precursor preparation of hydrophilic medicine and preparation method thereof |
| AU2020282018A1 (en) | 2019-05-29 | 2022-01-06 | Camurus Ab | Lipid-controlled release compositions |
| CN113368041B (en) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | Pharmaceutical composition, sustained-release preparation and preparation method thereof |
| WO2022235186A1 (en) * | 2021-05-04 | 2022-11-10 | Camurus Ab | Compositions and methods for treating neuroendocrine tumors |
| WO2024263085A1 (en) * | 2023-06-20 | 2024-12-26 | Camurus Ab | Compositions and methods for treating acromegaly |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324794C1 (en) * | 2003-11-07 | 2010-12-02 | Camurus Ab | Somatostatin analogue formulations |
| DK1682091T3 (en) * | 2003-11-07 | 2017-05-15 | Camurus Ab | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| GB0417388D0 (en) | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
| CA2575906C (en) | 2004-08-04 | 2014-04-15 | Camurus Ab | Compositions forming non-lamellar dispersions |
| ES2458992T3 (en) * | 2005-01-14 | 2014-05-07 | Camurus Ab | GnRH analog formulations |
| CA2595385C (en) * | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
| CN101193652B (en) * | 2005-04-08 | 2011-11-02 | 安米林药品公司 | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| US8546326B2 (en) * | 2005-06-06 | 2013-10-01 | Camurus Ab | Glp-1 analogue formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
| EA028040B1 (en) * | 2011-12-05 | 2017-09-29 | Камурус Аб | Pre-formulation forming a liquid crystalline in vivo composition, method of delivery of a bioactive agent using the same, method for preparation thereof and method of treatment by administering the same |
| KR102139080B1 (en) * | 2012-05-25 | 2020-07-29 | 카무러스 에이비 | Somatostatin receptor agonist formulations |
| US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
| AU2017336199B2 (en) * | 2016-09-27 | 2020-08-20 | Camurus Ab | Mixtures and formulations comprising an alkyl ammonium EDTA salt |
-
2012
- 2012-05-25 SI SI201232066T patent/SI2714004T1/en unknown
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-25 PL PL12731315.3T patent/PL2714004T3/en unknown
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/en active IP Right Grant
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/en active Active
- 2012-05-25 ES ES12731315T patent/ES2984717T3/en active Active
- 2012-05-25 HR HRP20240781TT patent/HRP20240781T1/en unknown
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 EA EA201391675A patent/EA036213B1/en not_active IP Right Cessation
- 2012-05-25 RS RS20240722A patent/RS65702B1/en unknown
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/en active Active
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/en active
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/en active Active
- 2012-05-25 PT PT127313153T patent/PT2714004T/en unknown
- 2012-05-25 TW TW101118843A patent/TWI624271B/en active
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/en active Active
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en active Application Filing
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 MX MX2013013401A patent/MX361716B/en active IP Right Grant
- 2012-05-25 HU HUE12731315A patent/HUE067389T2/en unknown
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/en not_active Application Discontinuation
- 2012-05-25 EP EP24175676.6A patent/EP4427814A3/en active Pending
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/en active
- 2012-05-25 LT LTEPPCT/EP2012/059917T patent/LT2714004T/en unknown
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-28 AR ARP120101869A patent/AR086577A1/en unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 NI NI201300127A patent/NI201300127A/en unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/en unknown
- 2013-11-22 GT GT201300292A patent/GT201300292A/en unknown
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/en unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/en unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550A1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/en unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/en unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/en unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/en active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en not_active Abandoned
-
2024
- 2024-09-18 US US18/889,001 patent/US20250121035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003365A1 (en) | Pharmaceutical formulation comprising diacylglycerol and / or tocopherol, phosphatidylcholine, biocompatible organic mono-alcoholic solvent comprising ethanol, polar solvent, and a somatostatin analog as active ingredient; process to prepare it; pharmaceutical kit; use in the treatment of acromegaly and cancers, among others. | |
| BR112015025172A2 (en) | pharmaceutical composition | |
| PE20141297A1 (en) | ROBUST PEPTIDIC FORMULATIONS OF CONTROLLED RELEASE | |
| AR083016A1 (en) | LIQUID FORMULATIONS FOR AGRICULTURE WITH BETTER STABILITY | |
| AR106049A1 (en) | CONTROLLED RELEASE FORMULATIONS | |
| BR112017013471A2 (en) | PRE-FORMULATION, PHARMACEUTICAL FORMULATION, DEPOSIT COMPOSITION, METHODS FOR THE ADMINISTRATION OF A BIOACTIVE AGENT TO A HUMAN OR NON-HUMAN ORGANISM, FOR THE PREPARATION OF A LIQUID CRYSTALLINE COMPOSITION, FOR THE TREATMENT OR NUMBER OF AN INDIVIDUAL, AN INDIVIDUAL A PRE-FORMULATION FOR A SUBJECT WHO NEEDS IT, PROCESS FOR FORMING A PRE-FORMULATION, USE OF A NON-LIQUID CRYSTALLINE MIXTURE WITH LOW VISCOSITY, PRE-COMPLETED ADMINISTRATION DEVICE, AND, KIT. | |
| PE20191714A1 (en) | POLYMERIC NANOPARTICULA OF FINASTERIDE AND MINOXIDIL, PREPARATION PROCESS, AQUEOUS SUSPENSION CONTAINING THE SAME, PHARMACEUTICAL COMPOSITION, AND ITS USE | |
| DE602005008247D1 (en) | LIQUID DEPOT FORMULATIONS | |
| DK1845942T3 (en) | GnRH analog formulations | |
| BR112012015433B8 (en) | substantially anhydrous pharmaceutical composition for cutaneous application | |
| UY28366A1 (en) | CHEMICAL COMPOUNDS | |
| MX2019003520A (en) | MIXTURES AND FORMULATIONS INCLUDING AN ALKYL AMMONIUM SALT OF ETHYLENEDIAMINOTETRAACETIC ACID (EDTA). | |
| AR099097A1 (en) | WATERPROOF SUSPOEMULSION CONTAINING l-CIALOTRINE AND METHODS TO PRODUCE AND USE THE SAME | |
| BR112017017643A2 (en) | topical pharmaceutical formulation | |
| PH12014502614A1 (en) | Somatostatin receptor agonist formulations | |
| CO2018006865A2 (en) | Methods and compositions for treating a stream comprising crude oil and water | |
| AR105691A1 (en) | METHOD, COMPOSITION AND SET OF ELEMENTS TO TREAT Erectile Dysfunction | |
| CO2018000526A2 (en) | Concentrate containing alprostadil | |
| HK1239563A1 (en) | Controlled-release formulations | |
| CO2018000525A2 (en) | Concentrate containing alprostadil | |
| AR109723A1 (en) | FORMULATIONS CONTAINING A SOMATOSTATINE RECEIVER AGONIST | |
| PE20180458A1 (en) | METHOD AND COMPOSITION AND KIT TO TREAT ERECTILE DYSFUNCTION | |
| AR100815A1 (en) | TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE |